MPM Capital to invest $850m in firms using novel tech to make cancer medication
Venture capitalists are pouring money into start-ups focused on mRNA, after seeing the success Moderna and Pfizer had producing mRNA Covid-19 vaccines
06 October 2021 - 17:42
byAkayla Gardner
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
MPM Capital, a Boston-based life sciences investment firm, has raised $850m for its fund that will invest in companies developing cancer drugs, including those experimenting with methods used in some Covid-19 vaccines.
The new fund will invest in private and public companies that are developing oncology treatments and using cell, gene and RNA therapies, the venture capital fund said in a statement on Wednesday. MPM’s first fund investing in cancer research start-ups raised $471m.
“The companies that we invest in are all motivated to transform the lives of patients,” said Christiana Bardon, a managing partner at BioImpact Capital, the MPM affiliate that’s managing the fund.
Venture capitalists are pouring money into start-ups focused on so-called messenger RNA, an innovative method which sends signals to cells to make proteins, after seeing the success Moderna and Pfizer had producing mRNA Covid-19 vaccines. Scientists are hopeful the technology can be used to treat other diseases including cancer, but creating drugs remains theoretical. Because the platform is so new, mRNA vaccines have also been subject to disinformation campaigns.
MPM has previously backed companies such as Orna Therapeutics, which seeks to develop low-cost RNA cancer drugs.
Bloomberg News. More stories like this are available on bloomberg.com
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
MPM Capital to invest $850m in firms using novel tech to make cancer medication
Venture capitalists are pouring money into start-ups focused on mRNA, after seeing the success Moderna and Pfizer had producing mRNA Covid-19 vaccines
MPM Capital, a Boston-based life sciences investment firm, has raised $850m for its fund that will invest in companies developing cancer drugs, including those experimenting with methods used in some Covid-19 vaccines.
The new fund will invest in private and public companies that are developing oncology treatments and using cell, gene and RNA therapies, the venture capital fund said in a statement on Wednesday. MPM’s first fund investing in cancer research start-ups raised $471m.
“The companies that we invest in are all motivated to transform the lives of patients,” said Christiana Bardon, a managing partner at BioImpact Capital, the MPM affiliate that’s managing the fund.
Venture capitalists are pouring money into start-ups focused on so-called messenger RNA, an innovative method which sends signals to cells to make proteins, after seeing the success Moderna and Pfizer had producing mRNA Covid-19 vaccines. Scientists are hopeful the technology can be used to treat other diseases including cancer, but creating drugs remains theoretical. Because the platform is so new, mRNA vaccines have also been subject to disinformation campaigns.
MPM has previously backed companies such as Orna Therapeutics, which seeks to develop low-cost RNA cancer drugs.
Bloomberg News. More stories like this are available on bloomberg.com
Oxford Nanopore soars 47% in London trading debut
Start-up that aims to ‘rewire the brain’ raises $70m in IPO
Sanofi to pull the plug on mRNA Covid-19 vaccine after rivals’ success
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Related Articles
Merck to buy Acceleron Pharma for $11.5bn
US drug firms say $26bn opioid settlement will proceed
Vaccine booster after six months provides stronger protection, says J&J
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.